WestGene

Executive Summary

WestGene is a clinical-stage Chinese biotechnology company pioneering advanced cell and gene therapies for oncology. Founded in 2015 and headquartered in Shanghai, the company focuses on engineered cell therapies, including CAR-T and TCR-T products, as well as gene-editing approaches. With a workforce of 200-500 employees, WestGene is currently advancing its pipeline through Phase 2 clinical trials, aiming to deliver innovative and accessible cancer treatments. The company's strategy leverages China's rapidly evolving regulatory environment and growing biotech ecosystem to develop next-generation immunotherapies with improved efficacy and safety profiles. WestGene's emphasis on cost-effective manufacturing and novel target discovery positions it as a potential leader in the competitive cell therapy landscape, particularly in solid tumors where current treatments have limited success.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead CAR-T candidate in solid tumors55% success
• Q4 2026IND approval for novel TCR-T therapy targeting hepatocellular carcinoma60% success
• Q2 2027Strategic partnership with major pharma for gene-editing platform40% success